Fresenius Medical Care AG

Fresenius Medical Care AG(FMS)股票分析

$22.130

+0.606 (+2.74%)收盘时

Loading chart…
最高
22.280
开盘
21.990
成交量加权均价
22.08
成交量
1.46M
市值
11.25B
最低
21.840
成交额
32.29M
企业价值/息税折旧摊销前利润(TTM)
5.74

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers.

AI 分析 of Fresenius Medical Care AG (FMS)

持有

Fresenius Medical Care AG is not a good buy right now. The current price is $21.06, and the RSI is at 31.076, indicating oversold conditions. However, the forward P/E ratio is 8.5763, suggesting potential undervaluation, but the recent downgrades from analysts and a significant 23.17% decline over the past year raise concerns. The main risk is the potential for further declines in U.S. dialysis volumes, as indicated by BNP Paribas's downgrade.

估值指标

Fresenius Medical Care AG(FMS)当前预期市盈率为 8.58,5 年平均预期市盈率为 12.83。

预期市盈率

低估
5 年均值 P/E
12.83
当前P/E
8.58
高估
16.46
低估
9.20

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
7.18
当前EV/EBITDA
5.74
高估
8.13
低估
6.24

预期市销率

合理
5 年均值 P/S
0.63
当前P/S
0.57
高估
0.76
低估
0.51

持有 FMS 的大户

P

Pzena Investment Management, Inc.

+ 持有FMS

+6.68%

3个月收益率

C

Cobas Asset Management, SGIIC, SA

+ 持有FMS

+4.91%

3个月收益率

F

Fresenius SE & Co. KGaA

+ 持有FMS

-8.06%

3个月收益率

事件时间线

2026-10-07 (ET)

11:30:00

Fresenius Medical Trading Resumes

11:00:00

Fresenius Medical Appoints Shervin Korangy as CEO

11:00:00

Fresenius Medical Trading Halted, News Pending

2026-05-28 (ET)

07:10:00

Fresenius Medical Care Launches €1B Share Buyback Program

2026-05-26 (ET)

07:10:00

Fresenius Medical Care Plans €1B Share Buyback

资讯

FMS 常见问题 —— 由 Alphio AI 解答

Fresenius Medical Care AG, formerly Fresenius Medical Care AG & Co. KGaA is a Germany-based kidney dialysis institute. The Company provides dialysis care and related services to persons suffering from end-stage renal disease (ESRD) and offers other extracorporeal therapies, as well as other healthcare services. It has two operating segments such as care delivery segment which consolidates the global health care services business and care enablement segment includes research and development (R&D), manufacturing, supply chain, and commercial operations. It develops and manufactures health care products, which includes dialysis and non-dialysis products. Such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment. Its non-dialysis products include acute cardiopulmonary and apheresis products. It owns, operates, or manages dialysis clinics sells products to other dialysis providers. It operates in the Healthcare sector.

Fresenius Medical Care AG is not a good buy right now. The current price is $21.06, and the RSI is at 31.076, indicating oversold conditions. However, the forward P/E ratio is 8.5763, suggesting potential undervaluation, but the recent downgrades from analysts and a significant 23.17% decline over the past year raise concerns. The main risk is the potential for further declines in U.S. dialysis volumes, as indicated by BNP Paribas's downgrade.

暂无帖子

注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易